Sharemaestro company-news research for Heron Therapeuti (HRTX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest HRTX news and sentiment
Heron Therapeuti
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
Early balanced news score
16/100 evidence confidence
84% direct company focus
4 current stories across 3 publishers
Current company news
Early balanced news score
4 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone48/100
→
Published 30-day score50/100
Latest source headline
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc.
MarketBeat · 06 Sep 2026 07:50
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
4 current stories are mapped specifically to HRTX.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.038.
Confidence is 16/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
84%/100
Company news4 company stories
85/100
Story agreement15/100 difference
News history
Daily score and story count over 30 days
21 Aug05 Sep19 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.038 after freshness weightingSource breadth60
3 independent publishersCompany relevance84
share tied directly to this companyFreshness8
recency-weighted evidenceAgreement85
how closely stories agreePublisher mix45
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks19 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
20 Mar16 Jun11 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
11 Sep 202650USD 0.3155-8.3%
04 Sep 202648USD 0.3439+5.3%
28 Aug 202646USD 0.3266+2.6%
21 Aug 202644USD 0.3182-5.5%
14 Aug 202644USD 0.3367-31.4%
07 Aug 202646USD 0.4908-1.1%
31 Jul 202647USD 0.4962+8.9%
24 Jul 202650USD 0.4558-3.2%
Provisional evidence
News subjects
What is shaping the score
Earnings493 stories · 75%
Analyst action501 stories · 25%
Source mix
Where the evidence comes from
vinanet.vn251 stories · 25%
Vinanet251 stories · 25%
MarketBeat581 stories · 25%
Moomoo501 stories · 25%
Recurring subjects
Subjects appearing most often
Life Sciences2Financial Markets2Earnings1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
04 May50 neutral17 Sep 05:42
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 17 Sep 05:42 | 50 | +1 | 14/100 (-9) | 4 (-19) | Provisional |
| 06 Sep 23:59 | 49 | +6 | 23/100 (-9) | 23 (-13) | Provisional |
| 23 Aug 23:59 | 43 | -1 | 32/100 (-1) | 36 (+1) | Provisional |
| 20 Aug 23:59 | 44 | -1 | 33/100 (0) | 35 (+2) | Provisional |
| 17 Aug 23:59 | 45 | +2 | 33/100 (-11) | 33 (-1) | Provisional |
| 13 Aug 23:59 | 43 | +0 | 44/100 (-3) | 34 (+2) | Measured |
| 12 Aug 23:59 | 43 | -1 | 47/100 (-1) | 32 (+1) | Measured |
| 11 Aug 23:59 | 44 | +1 | 48/100 (-4) | 31 (+1) | Measured |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#158Tone
MarketBeatDirect company coverageStored article
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc.
BlackRock Inc. has acquired over 10.55 million shares of Heron Therapeutics (NASDAQ:HRTX) in the second quarter, representing a 5.57% stake valued at approximately $4.5 million. Despite this significant institutional investment, which brings total institutional ownership to 80.01%, analysts maintain a cautious "Hold" consensus rating with an average price target of $2.00. The biotechnology company reported a quarterly loss of $0.03 per share and revenue below analyst estimates, with its stock currently trading near its 52-week low.
EarningsFinancial MarketsLife Sciences
- Published
- 06 Sep 2026 07:50
- News subject
- Earnings
- Why this score
- Institutional or insider buying
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 71.4% of the score · 11.5d old
- Duplicates
- 1 consolidated
#225Tone
vinanet.vnDirect company coverageScored from headline
Heron (HRTX) Quarterly Figures: Profit Per Share Falls Below Its Benchmark at the Close; Post-Earnings: The Market Price Advances 2.91% on the Day - Special Dividend Alert
- Published
- 23 Aug 2026 13:40
- News subject
- Earnings
- Why this score
- Missed expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 54/100
- 30-day weight
- 17% of the score · 25.2d old
- Duplicates
- 1 consolidated
#325Tone
VinanetDirect company coverageScored from headline
Heron (HRTX) Results Review: EPS Comes in Below Forecast on the Day; Price Reaction: Shares Move 4.13% Down in Latest Trading - Earnings Turnaround
- Published
- 20 Aug 2026 18:37
- News subject
- Earnings
- Why this score
- Missed expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 53/100
- 30-day weight
- 11.6% of the score · 28.0d old
- Duplicates
- 1 consolidated
#4—Not directional
MoomooDirect company coverageStored article
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating
H.C. Wainwright has reiterated its Hold rating for Heron Therapeutics (HRTX.US). The article does not provide further details on the reasons for this rating or any financial analysis.
Financial MarketsLife Sciences
- Published
- 20 Aug 2026 02:10
- News subject
- Analyst action
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.7d old
- Duplicates
- 1 consolidated
Earlier company news
HRTX news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 63 older HRTX headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to HRTX, but the headline and available text are not mainly about Heron Therapeuti. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of HRTX sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.